文献速递肿瘤 PET/CT

[18F]FAPI-04 PET/CT对疑似复发肝细胞癌的诊断效能:与增强CT/MRI的前瞻性比较

Diagnostic performance of [18F]FAPI-04 PET/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT/MRI.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-15

前瞻性纳入44例疑似肝细胞癌复发患者共129个病灶,比较[18F]FAPI-04 PET/CT、增强CT/MRI及两者联合的诊断效能,以病理或影像随访为标准。联合显像的灵敏度、特异度和准确率均优于单独增强CT/MRI和单独[18F]FAPI-04 PET/CT(均P<0.001),并改变了22.7%患者的治疗管理。

要点

  • 联合[18F]FAPI-04 PET/CT与增强CT/MRI较两者单独使用显著提高诊断灵敏度、特异度和准确率。
  • 复发灶SUVmax 8.1、LBR 5.4均显著高于治疗所致病灶的3.65和1.9(P<0.001)。
  • SUVmax截断值5.1和LBR截断值2.3用于鉴别复发与治疗所致病灶。

核心结论

  • [18F]FAPI-04 PET/CT联合增强CT/MRI显著提高鉴别复发肝细胞癌与治疗所致病灶的灵敏度、特异度和准确率。
  • [18F]FAPI-04 PET可能是检测复发肝细胞癌有前景的显像方法。

研究设计与样本

  • 前瞻性纳入切除或局部区域治疗后疑似肝细胞癌复发、且接受增强CT/MRI和[18F]FAPI-04 PET/CT的患者。
  • 对每位患者或每个病灶,增强CT/MRI和[18F]FAPI-04 PET/CT分别按阳性、阴性或不确定进行三点量表评分。
  • 以组织病理学或影像随访为标准,采用McNemar检验比较增强CT/MRI、[18F]FAPI-04 PET/CT及两者联合的诊断效能。
  • 分析[18F]FAPI-04 PET/CT所得病灶SUVmax和病灶-本底比(LBR),计算鉴别复发与治疗所致病灶的截断值。
  • 共分析44例患者129个病灶,其中31例患者91个病灶证实为复发肝细胞癌,38个病灶为治疗所致病灶。

主要发现

  • 病灶分析中,联合[18F]FAPI-04 PET/CT与增强CT/MRI的灵敏度为86.8%,高于增强CT/MRI的70.3%和[18F]FAPI-04 PET/CT单独的72.5%(均P<0.001)。
  • 联合显像特异度为89.5%,高于增强CT/MRI的42.1%和[18F]FAPI-04 PET/CT单独的52.6%(均P<0.001)。
  • 联合显像准确率为87.6%,高于增强CT/MRI的62.0%和[18F]FAPI-04 PET/CT单独的66.7%(均P<0.001)。
  • 联合显像改变了22.7%患者的治疗管理。
  • 复发肝细胞癌(n=91)的SUVmax为8.1、LBR为5.4,均显著高于治疗所致病灶(n=38)的SUVmax 3.65和LBR 1.9(P<0.001)。

关键数值与推荐

  • 以SUVmax截断值5.1鉴别复发与治疗所致病灶,[18F]FAPI-04 PET/CT的灵敏度为83.5%、特异度为78.9%。
  • 以LBR截断值2.3鉴别复发与治疗所致病灶,[18F]FAPI-04 PET/CT的灵敏度为96.2%、特异度为63.2%。

临床怎么用

  • 作者认为,[18F]FAPI-04 PET/CT联合增强CT/MRI可显著提高鉴别复发肝细胞癌与治疗所致病灶的诊断效能。
  • 作者认为,[18F]FAPI-04 PET可能是检测复发肝细胞癌有前景的显像方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the diagnostic performance of [18F]FAPI-04 PET/CT in differentiating hepatocellular carcinoma (HCC) recurrence from treatment-induced lesions (TILs) after therapy and compare it with contrast-enhanced CT/MRI (Ce-CT/MRI). METHODS: Patients with suspected HCC recurrence after resection or local-regional therapy, who underwent Ce-CT/MRI and [18F]FAPI-04 PET/CT, were prospectively enrolled. For each patient or lesion, a three-point-scale (positive, negative, or equivocal) was assigned to Ce-CT/MRI and [18F]FAPI-04 PET/CT. The diagnostic performances of Ce-CT/MRI, [18F]FAPI-04 PET/CT, and their combination were compared by McNemar's test, with histopathology or radiographic follow-up as a reference standard. The maximum standardized uptake value (SUVmax) and lesion-to-background ratio (LBR) of lesions derived from [18F]FAPI-04 PET/CT were analyzed, and the cut-off points for distinguishing between HCC recurrence and TILs were calculated. RESULTS: A total of 44 patients with 129 lesions were analyzed, of which 31 patients (91 lesions) were proved to be recurrent HCC and 38 lesions were TILs. On lesion-based analysis, the combination of [18F]FAPI-04 PET/CT with Ce-CT/MRI demonstrated superior sensitivity (86.8% vs. 70.3% vs. 72.5%), specificity (89.5% vs. 42.1% vs. 52.6%), and accuracy (87.6% vs. 62.0% vs. 66.7%) compared to Ce-CT/MRI and [18F]FAPI-04 PET/CT alone (all P < 0.001). The combination altered therapy management in 22.7% of patients. On semiquantitative analysis, the SUVmax and LBR of [18F]FAPI-04 PET in HCC recurrence (n = 91) were significantly higher than those in TILs (n = 38) (SUVmax: 8.1 vs. 3.65, P < 0.001; LBR: 5.4 vs. 1.9, P < 0.001). Using cutoff points of 5.1 for SUVmax and 2.3 for LBR, [18F]FAPI-04 PET/CT exhibited high sensitivity and specificity in differentiating recurrent HCC from TILs, with 83.5%, 78.9% and 96.2%, 63.2%, respectively. CONCLUSIONS: The combination of [18F]FAPI-04 PET/CT with Ce-CT/MRI significantly improved diagnostic sensitivity, specificity, and accuracy in differentiating recurrent HCC from TILs. [18F]FAPI-04 PET may be a promising imaging modality in detecting recurrent HCC. TRIAL REGISTRATION: clinicaltrials.gov: NCT05485792.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liang J, Weng S, Zhang J, et al. Diagnostic performance of [18F]FAPI-04 PET/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT/MRI. Eur J Nucl Med Mol Imaging. 2025. PMID: 40232335. doi:10.1007/s00259-025-07273-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。